BHST BIOHARVEST SCIENCES INC. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723464 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $34.51M | $25.19M | $12.67M |
| Cost of revenue | $14.03M | $11.25M | $7.04M |
| Gross profit | $20.48M | $13.94M | $5.63M |
| R&D expense | $5.31M | $4.80M | $3.37M |
| SG&A expense | $4.93M | $4.40M | $4.48M |
| Operating income | -$5.58M | -$6.99M | -$9.97M |
| Pretax income | -$11.06M | -$12.90M | -$12.56M |
| Income tax | -$76,000 | -$8,000 | $0 |
| Net income | -$11.13M | -$12.91M | -$12.56M |
| EBITDA | -$3.95M | -$5.74M | -$9.13M |
| EPS (basic) | -0.60 | -0.80 | -0.93 |
| EPS (diluted) | — | — | — |
| Balance sheet | |||
| Cash & equivalents | $23.02M | $2.39M | $5.36M |
| Receivables | $1.98M | $1.12M | $808,000 |
| Inventory | $4.56M | $3.65M | $2.47M |
| Current assets | $30.50M | $7.86M | $9.05M |
| PP&E, netmay include right-of-use assets (IFRS) | $8.33M | $7.75M | $3.93M |
| Total assets | $47.66M | $25.00M | $15.00M |
| Current liabilities | $7.68M | $14.26M | $26.47M |
| Short-term debt | $149,000 | $3.90M | $0 |
| Total liabilities | $22.22M | $23.67M | $29.86M |
| Shareholders' equity | $25.45M | $1.33M | -$14.85M |
| Cash flow statement | |||
| Operating cash flow | -$7.23M | -$6.68M | -$8.52M |
| Capital expenditure | $2.35M | $2.83M | $1.47M |
| Free cash flow | -$9.58M | -$9.52M | -$10.00M |
| Investing cash flow | -$2.37M | -$3.03M | -$1.47M |
| Financing cash flow | $30.19M | $6.78M | $13.56M |
| Depreciation & amortization | $1.62M | $1.25M | $840,000 |
| Stock-based compensation | — | $601,000 | $563,000 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.